Financials
Financial year 2025
Z+PHARMA from Beveren-Kruibeke-Zwijndrecht, company number BE0453060967, closed financial year 2025 with a result of € 26,951 after tax. For that financial year Z+PHARMA recorded a gross margin of € 376,566 and equity of € 521,934. Compared with financial year 2024, the result moved from € 195,315 to € 26,951. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 24, 2025.
€ 521,934
▼ 19% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 26,951
▼ 86% vs 2024
Profit after tax over the fiscal year.
€ 8,158
▼ 12% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 150,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
4.8
▲ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 243,477
▼ 12% vs 2024
€ 50,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 351
▼ 56% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 114,638
▼ 11% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 10,246
▼ 74% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 433,663 | € 465,770 | € 655,638 | € 376,566 | ▼ 43% |
| Profit after taxes | € 78,866 | € 65,879 | € 195,315 | € 26,951 | ▼ 86% |
| Equity | € 443,476 | € 443,476 | € 644,984 | € 521,934 | ▼ 19% |
| Total debts | € 782,336 | € 772,102 | € 183,011 | € 126,485 | ▼ 31% |
| Cash | € 75,281 | € 113,698 | € 9,260 | € 8,158 | ▼ 12% |
| Land & buildings | € 196,525 | € 171,781 | € 141,055 | € 116,618 | ▼ 17% |
| Retained profit | € 431,076 | € 431,076 | € 626,392 | € 460,434 | ▼ 26% |
| Dividend | € 78,000 | € 65,879 | € 0 | € 150,000 | |
| Bank debt | € 546,877 | € 465,129 | € 15,092 | € 0 | ▼ 100% |
| Balance sheet total | € 1,225,812 | € 1,215,578 | € 827,995 | € 648,420 | ▼ 22% |
| Employees (FTE) | 3.9 | 4.4 | 4.6 | 4.8 | ▲ 0.2 |
Key figures of Z+PHARMA, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.
What happened to Z+PHARMA?
What happened at Z+PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 26,951 (▼ 86% vs 2024). Source: NBB ↗
- Jozef Colruyt became a director. NBB
- Kris Castelein became a director. NBB
- Stefan Goethaert became a director. NBB
- Stefaan Vandamme became a director. NBB
- Jo Willemyns became a director. NBB
- New establishment in Beveren-Kruibeke-Zwijndrecht. KBO
- Start of the company according to the CBE. KBO
In short
From € 78,866 profit in 2021 to € 26,951 profit in 2025.
Paid € 95,037 in corporate taxes since 2021.
Best year ever: 2024, with € 195,315 profit.
On average € 78,500 of value added per employee in 2025.
A new publication or filing at Z+PHARMA? We notify you, reason included.
Follow Z+PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of NEWPHARMA GROUP comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Z+PHARMABehind Z+PHARMA are Jozef Colruyt, Kris Castelein, Stefan Goethaert, Stefaan Vandamme and Jo Willemyns. The shares are held by NEWPHARMA GROUP (100%).
Directors
According to the 2025 annual accounts
Jozef Colruyt
Bestuurder
since 2023
Kris Castelein
Bestuurder
since 2023
Stefan Goethaert
Bestuurder
since 2023
Stefaan Vandamme
Bestuurder
since 2023
Jo Willemyns
Bestuurder
since 2023
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Statiestraat 131
2070 Beveren-Kruibeke-Zwijndrecht
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
AMAZON-02 - Amazon.com, Inc., US
Website info
Features
Security
Details
- Company number
- 0453.060.967
- VAT number
- BE 0453.060.967
- Registered office
- Statiestraat 131, 2070 Beveren-Kruibeke-Zwijndrecht
- Names & denominations
- Z+PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 1 July 1994
- Peppol
- Active · Active since 24 Nov 2023
- Contact
- zpharma.be [email protected] 032528001
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers